Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,242.00    94.00 (4.38%)
Bid:
2,216.00
Ask:
2,232.00
Spread: 16.00 (0.722%)
Market Cap: £1.49b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
25th Sep 20206:14 pmRNSDirector/PDMR Shareholding
23rd Sep 20209:35 amRNSDirector/PDMR Shareholding
16th Sep 202012:16 pmRNSDirector/PDMR Shareholding
15th Sep 20205:52 pmRNSDirector/PDMR Shareholding
9th Sep 202012:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
8th Sep 20203:16 pmRNSApplication for Additional Listing
8th Sep 20207:00 amRNSPreliminary Results
1st Sep 20201:03 pmRNSTotal Voting Rights
3rd Aug 20204:15 pmRNSBlock listing Interim Review
1st Jul 202010:41 amRNSTotal Voting Rights
30th Jun 20203:45 pmRNSNOTIFICATION OF MAJOR HOLDINGS
29th Jun 20207:00 amRNSDirectorate Appointment
14th May 20206:23 pmRNSApplication for Block Listing
1st May 20203:04 pmRNSTotal Voting Rights
30th Apr 202010:24 amRNSCompliance with LR 9.2.6ER(1)
22nd Apr 20205:47 pmRNSDirector/PDMR Shareholding
21st Apr 202012:14 pmRNSNotification of Major Holdings
20th Apr 20209:28 amRNSDirector/PDMR Shareholding
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:52 pmRNSTotal Voting Rights
27th Feb 20207:00 amRNSInterim Results
26th Feb 202012:44 pmRNSNOTIFICATION OF MAJOR HOLDINGS
17th Feb 20205:27 pmRNSNotification of Major Holdings
7th Feb 20209:03 amRNSNotification of Major Holdings
3rd Feb 202010:51 amRNSBlock listing Interim Review
23rd Jan 20203:52 pmRNSNotification of Major Holdings
2nd Jan 202010:02 amRNSTotal Voting Rights
12th Dec 20192:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Dec 20194:45 pmRNSTotal Voting Rights
20th Nov 20197:00 amRNSAppointment of Chief Financial Officer
15th Nov 20196:18 pmRNSDirector/PDMR Shareholding
14th Nov 20191:23 pmRNSResult of AGM
14th Nov 20197:00 amRNSAGM TRADING UPDATE
1st Nov 201912:05 pmRNSTotal Voting Rights
14th Oct 20198:00 amRNSAnnual Report and Annual General Meeting
10th Oct 20193:30 pmRNSDirector/PDMR Shareholding
3rd Oct 20193:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Oct 20193:38 pmRNSNotification of Major Holdings
1st Oct 20195:23 pmRNSTotal Voting Rights
20th Sep 201912:38 pmRNSDirector/PDMR Shareholding
18th Sep 20196:09 pmRNSDirector/PDMR Shareholding
17th Sep 20191:24 pmRNSDirector/PDMR Shareholding
12th Sep 20192:59 pmRNSDirector/PDMR Shareholding
11th Sep 20198:02 amRNSCORRECTION: Outcome of IntelliGen Litigation
11th Sep 20197:00 amRNSOutcome of latest IntelliGen Litigation
10th Sep 20197:00 amRNSOUTCOME IN LATEST INTELLIGEN LITIGATION
5th Sep 20197:00 amRNSPreliminary Results
22nd Aug 20197:00 amRNSAppointment of Chief Executive Officer
1st Aug 20195:49 pmRNSBlock listing Interim Review
1st Aug 20195:46 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.